Cited by 6Cancer survivorship and careCAR-T cell therapy researchNursing care and research

Psychosocial characteristics of patients undergoing cellular immunotherapies and their caregivers across time

Open access
Kirtane, Kedar, Reblin, Maija, Oswald, Laura B., Irizarry-Arroyo, Nathaly, McCormick, Rachael, Locke, Frederick L., Ketcher, Dana·2023·Leukemia & Lymphoma

Abstract

Chimeric antigen receptor T-cells and other immunotherapies have markedly changed the paradigm of treatment for patients with relapsed or refractory hematologic malignancies. While notable in efficacy, immunotherapy is characterized by a significant possibility of life-threatening side effects. Consequently, patients are often required to have informal family caregivers present and to stay near the treating center for several weeks after cell infusion. Further, the responsibility of managing a great deal of physical care and emotional support falls to these caregivers. Given the novelty of immunotherapy treatment, there is a need to better understand the psychosocial experience of patients receiving this treatment and their caregivers. This article describes the psychosocial characteristics of patients undergoing cellular immunotherapies and their caregivers across time, including patient/caregiver distress, coping, and caregiver burden and preparedness.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/10428194.2022.2148216

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Quantitative studies have shown that 15% of family caregivers of patients receiving CAR-T-cell therapy experience moderate to severe burdens, and 47.7% exhibit symptoms of depression.

    “Quantitative studies have shown that 15% of family caregivers of patients receiving CAR-T-cell therapy experience moderate to severe burdens, and 47.7% exhibit symptoms of depression.”

    From The burdens, coping strategies, and unmet needs of family caregivers of Chinese patients with lymphoma receiving commercial CAR-T-cell therapy: A qualitative study (2026) · cites this paper as [27]

    The Results report caregiver burden and depression among people receiving cellular immunotherapies, but give mean scores rather than the claimed percentages. They describe average caregiver burden as mild and do not report that 15% had moderate-to-severe burden or that 47.7% had depressive symptoms. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

5 of the 33 references couldn’t be matched to a known paper.

Research works printed but not linked: 2

  1. [2]Park JH, Rivière I, Gonen M, Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. New England Journal of Medicine. 2018; 378(5): 449– 459. 29385376 PMC6637939
  2. [11]Andrews SC. Caregiver burden and symptom distress in people with cancer receiving hospice care. Paper presented at: Oncology Nursing Forum 2001. 11683316

Cited by

Sorted by citations

Authors
Kirtane, K., Reblin, M., Oswald, L. B., Irizarry-Arroyo, N., McCormick, R., Locke, F. L., & Ketcher, D.
Affiliations
  • Moffitt Cancer Center (US)
  • University of Vermont (US)
  • University of Minnesota (US)
Corresponding author
Kirtane, Kedar
Venue
Leukemia & Lymphoma
Published
2022-11-23
Volume
64
Issue
2
Pages
364-370
ISSN
  • 1026-8022 (ISSN-L)
  • 1042-8194
  • 1029-2403
OpenAlex
W4309830166
Cited by
6
References
33
Citations by year
2026: 2 · 2025: 3 · 2024: 1
FWCI
0.42
Type
journal article
Language
en
Open access
Locations
  • Leukemia & lymphoma/Leukemia and lymphoma (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • ECOG-ACRIN (5UG1CA189828-07)
  • Federal Award (UG1CA189828)
Topics
  • Health Sciences › Medicine › Oncology › Cancer survivorship and care
  • Health Sciences › Medicine › Oncology › CAR-T cell therapy research
  • Health Sciences › Health Professions › Pharmacy › Nursing care and research
Keywords
CAR T-cell therapy, cellular immunotherapy, socio-psychological factors, caregivers, caregiver burden, caregiver preparedness, patient distress, coping, relapsed or refractory hematologic malignancies, time course
MeSH terms
Adaptation, Psychological, Humans, Immunotherapy, Quality of Life, Caregivers, Hematologic Neoplasms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review